US Lung Cancer Market

ID: MRFR/Pharma/11862-HCR
100 Pages
Vikita Thakur
Last Updated: April 06, 2026
US Lung Cancer Market Research Report: Size, Share, Trend Analysis By Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy), By Diagnosis Type (Imaging Tests, Biopsy, Sputum Cytology, Blood Tests), By Patient Demographics (Age, Gender, Smoking History, Geographic Location) and By Stage of Cancer (Early Stage, Locally Advanced Stage, Metastatic Stage) - Growth Outlook & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Treatment Type (USD Billion)
      1. 4.1.1 Chemotherapy
      2. 4.1.2 Radiation Therapy
      3. 4.1.3 Targeted Therapy
      4. 4.1.4 Immunotherapy
    2. 4.2 Pharmaceutical, BY Diagnosis Type (USD Billion)
      1. 4.2.1 Imaging Tests
      2. 4.2.2 Biopsy
      3. 4.2.3 Sputum Cytology
      4. 4.2.4 Blood Tests
    3. 4.3 Pharmaceutical, BY Patient Demographics (USD Billion)
      1. 4.3.1 Age
      2. 4.3.2 Gender
      3. 4.3.3 Smoking History
      4. 4.3.4 Geographic Location
    4. 4.4 Pharmaceutical, BY Stage of Cancer (USD Billion)
      1. 4.4.1 Early Stage
      2. 4.4.2 Locally Advanced Stage
      3. 4.4.3 Metastatic Stage
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Roche (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Merck & Co. (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 AstraZeneca (GB)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Novartis (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Pfizer (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Eli Lilly and Company (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Amgen (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 GSK (GB)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TREATMENT TYPE
    3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS TYPE
    4. 6.4 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    5. 6.5 US MARKET ANALYSIS BY STAGE OF CANCER
    6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
    9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    12. 6.12 PHARMACEUTICAL, BY TREATMENT TYPE, 2024 (% SHARE)
    13. 6.13 PHARMACEUTICAL, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
    14. 6.14 PHARMACEUTICAL, BY DIAGNOSIS TYPE, 2024 (% SHARE)
    15. 6.15 PHARMACEUTICAL, BY DIAGNOSIS TYPE, 2024 TO 2035 (USD Billion)
    16. 6.16 PHARMACEUTICAL, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    17. 6.17 PHARMACEUTICAL, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
    18. 6.18 PHARMACEUTICAL, BY STAGE OF CANCER, 2024 (% SHARE)
    19. 6.19 PHARMACEUTICAL, BY STAGE OF CANCER, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
      3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
      4. 7.2.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US US Lung Cancer Market Segmentation

US Lung Cancer Market By Treatment Type (USD Billion, 2025-2035)

  • Chemotherapy
  • Radiation Therapy
  • Targeted Therapy
  • Immunotherapy

US Lung Cancer Market By Diagnosis Type (USD Billion, 2025-2035)

  • Imaging Tests
  • Biopsy
  • Sputum Cytology
  • Blood Tests

US Lung Cancer Market By Patient Demographics (USD Billion, 2025-2035)

  • Age
  • Gender
  • Smoking History
  • Geographic Location

US Lung Cancer Market By Stage of Cancer (USD Billion, 2025-2035)

  • Early Stage
  • Locally Advanced Stage
  • Metastatic Stage

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035